Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting
Brief Summary: This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast during the month of Ramadan. The primary hypothesis is that during the 30 days of Ramadan fasting, treatment with sitagliptin (with or without metformin) compared to SU treatment (with or without metformin) results in a lower incidence of hypoglycemia in participants with T2DM.


Options:
A: Arm Label: Canagliflozin + Metformin; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Repaglinide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Repaglinide | Arm Label: Pioglitazone + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: Gliclazide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide | Arm Label: Glimepiride + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin + Metformin | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): Repaglinide + Metformin | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone + Metformin | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride + Metformin
B: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin
C: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin, Drug: Metformin | Arm Label: Sulfonylurea Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Sulfonylurea Therapy | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea Therapy
D: Arm Label: Intervention; Type: OTHER; Interventions: Other: FAST | Arm Label: Control; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: FAST; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Control

Answer: C